Respiratory news

AirFluSal MDI: a new LABA/corticosteroid inhaler

AirFluSal MDI: a new LABA/corticosteroid inhaler

AirFluSal MDI (salmeterol/fluticasone) is indicated...

Inhaler options multiply with launch of new salmeterol/fluticasone MDI

Inhaler options multiply with launch of new salmeterol/fluticasone MDI

Sereflo (salmeterol/fluticasone) is indicated for adults...

Pictorial inhaler guide published on MIMS website

Pictorial inhaler guide published on MIMS website

Images and key features of inhalers and other respiratory...

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Inhalers, a Guide to Breath-Actuated Devices

Inhalers, a Guide to Breath-Actuated Devices

Key features of dry powder and aerosol inhalers.

Alternative salmeterol/fluticasone dry powder inhaler for asthma and COPD

Alternative salmeterol/fluticasone dry powder inhaler for asthma and COPD

Aerivio Spiromax provides the same metered dose of...

Salmeterol/fluticasone dry powder inhaler approved for asthma

Salmeterol/fluticasone dry powder inhaler approved for asthma

AirFluSal Forspiro (salmeterol/fluticasone) is now...

NICE approves mepolizumab for refractory eosinophilic asthma

NICE approves mepolizumab for refractory eosinophilic asthma

Mepolizumab may be used within the NHS for the treatment...

Infographic: Improved steroid inhaler prescribing sees £2 million reduction in monthly spend

Infographic: Improved steroid inhaler prescribing sees £2 million reduction in monthly spend

Optimising prescribing of high-dose steroid inhalers...

New tiotropium inhaler for COPD patients

New tiotropium inhaler for COPD patients

Braltus uses the new Zonda inhaler to deliver the same...

New injectable antibody treatment for asthma

New injectable antibody treatment for asthma

Cinqaero (reslizumab) can be prescribed as add-on therapy...

BTS/SIGN asthma guidance updated with new treatment recommendations

BTS/SIGN asthma guidance updated with new treatment recommendations

The 2016 edition of the Scottish Intercollegiate Guidelines...

Flu vaccines for 2016/17 season

Flu vaccines for 2016/17 season

Flu vaccine listings in MIMS have been updated to reflect...

New cystic fibrosis combination drug not recommended for NHS use

New cystic fibrosis combination drug not recommended for NHS use

Orkambi (lumacaftor/ivacaftor), a new gene-specific...

Symbicort now available as metered-dose inhaler for COPD

Symbicort now available as metered-dose inhaler for COPD

Symbicort (formoterol/budesonide) is now available...

Inhaled levofloxacin offers new option for treatment of infection in cystic fibrosis

Inhaled levofloxacin offers new option for treatment of infection in cystic fibrosis

Quinsair (levofloxacin) is licensed in the management...

New cystic fibrosis treatment targets underlying cause of the disease

New cystic fibrosis treatment targets underlying cause of the disease

Orkambi (lumacaftor/ivacaftor) targets the F508del...

Lung disease treatment approved by NICE

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases